#breast cancer drugs

1 story

#clinical trial costs #drug pricing #elilly #generic drugs #india #kerala high court #novartis

Novartis and Eli Lilly Oppose India Breast Cancer Drug Price Cut Bid
Novartis and Eli Lilly oppose Kerala HC's bid to lower breast cancer drug prices in India, citing high global sales versus minimal local revenue.
The Economic Times · 1m